Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : H1 2021 results - AstraZeneca PLC

07/29/2021 | 10:02am EDT

Pascal Soriot, Chief Executive Officer, commenting on the results said:

"AstraZeneca has delivered another period of strong growth thanks to robust performances across all regions and disease areas, particularly Oncology, New CVRM and Fasenra in Respiratory. As a result, we have delivered further earnings progression, supported ongoing launches, and continued our investment in R&D.

We continue to advance our portfolio of life-changing medicines with further significant progress across disease areas. In Oncology, we recently presented Lynparza's OlympiA Phase III trial at the plenary session of the 2021 American Society of Clinical Oncology Annual Meeting, and we also shared the final results from Calquence's head-to-head trial with ibrutinib. In BioPharmaceuticals, the US approved Farxiga for chronic kidney disease and granted tezepelumab Priority Review to treat patients with asthma. Alexion will enable us to enhance our pipeline, extending the Company's presence in rare diseases and immunology with its complement biology.

Following the successful acquisition of Alexion, we are today updating our full-year 2021 guidance; our long-term goals to accelerate scientific discovery, invest for sustainable growth and deliver more benefits for patients remains unchanged."

Adrian Kemp

Company Secretary

AstraZeneca PLC

.

(C) 2021 M2 COMMUNICATIONS, source M2 PressWIRE

All news about ASTRAZENECA PLC
08:42aASTRAZENECA : Credit Suisse maintains a Buy rating
MD
08:26aSANOFI : - New research presented at IDWeek 2021 reinforces Sanofi :'s robust vaccines pip..
AQ
07:50aASTRAZENECA : Receives a Buy rating from Jefferies
MD
07:06aASTRAZENECA : 300,000 Covid-19 Jabs Land in Namibia
AQ
06:32aASTRAZENECA : Saphnelo is a first-in-class type I interferon receptor antibody shown to re..
PU
06:06aASTRAZENECA : Ghana Takes Custody of 1.5 Astrazeneca Doses Donation From Germany
AQ
05:06aASTRAZENECA : Govt - 4.7 Million Eligible Nigerians Have Received First Dose of Covid-19 V..
AQ
04:15aASTRAZENECA : Secures Japanese Regulatory Approval for Saphnelo as Treatment for Systemic ..
MT
03:06aASTRAZENECA : Covid-19 - Govt Says 1.8m Nigerians Fully Vaccinated
AQ
02:31aASTRAZENECA : Lupus Drug Gets Japanese Approval
MT
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 35 524 M - -
Net income 2021 5 008 M - -
Net Debt 2021 24 280 M - -
P/E ratio 2021 32,9x
Yield 2021 2,40%
Capitalization 182 B 182 B -
EV / Sales 2021 5,80x
EV / Sales 2022 4,71x
Nbr of Employees 76 100
Free-Float 96,3%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Last Close Price 117,38 $
Average target price 136,22 $
Spread / Average Target 16,0%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC16.97%181 937
JOHNSON & JOHNSON3.68%429 542
ROCHE HOLDING AG9.24%319 352
PFIZER, INC.19.37%244 283
NOVO NORDISK A/S48.08%227 557
ELI LILLY AND COMPANY34.09%205 250